<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04356170</url>
  </required_header>
  <id_info>
    <org_study_id>GORTEC 2019-01</org_study_id>
    <nct_id>NCT04356170</nct_id>
  </id_info>
  <brief_title>Trial Evaluating Adapted Chemotherapy in Patients With Squamous Carcinoma</brief_title>
  <acronym>TPFmORL</acronym>
  <official_title>A Phase II Randomized Trial, Non Comparative, Evaluating Chemotherapy Associated Cisplatin, 5-fluorouracil and Docetaxel at Adapted Doses in Patients With Locally Advanced Squamous Cell Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Groupe Oncologie Radiotherapie Tete et Cou</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Centre Leon Berard</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Groupe Oncologie Radiotherapie Tete et Cou</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to evaluate the efficacity of the combination of&#xD;
      cisplatin-5-FU and docetaxel in adapted doses in term of response to treatment without&#xD;
      toxicity&#xD;
&#xD;
      .&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      After explaining the treatment modalities, having read and explained the information letter&#xD;
      to them, patients who have signed the consent to participate in the trial and who meet the&#xD;
      inclusion criteria will be enrolled and randomized in the trial .&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 4, 2021</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">October 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacity of combination of TPFm</measure>
    <time_frame>8 weeks after the end of treatment</time_frame>
    <description>Success rate of patients at 8 weeks</description>
  </primary_outcome>
  <other_outcome>
    <measure>Overall survival</measure>
    <time_frame>3 months after the end of treatment</time_frame>
    <description>The time from date of randomization to date of death due to any cause</description>
  </other_outcome>
  <other_outcome>
    <measure>Progression free survival</measure>
    <time_frame>3 months after the end of treatment</time_frame>
    <description>The time from date randomization to date of first evidence of progression</description>
  </other_outcome>
  <other_outcome>
    <measure>incidence of local and/or locorégional failure</measure>
    <time_frame>3 months after the end of treatment</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Laryngeal preservation</measure>
    <time_frame>3 months after the end of treatment</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>incidence of distant metastatic failure</measure>
    <time_frame>3 months after the end of treatment</time_frame>
    <description>The time from the date of randomization and the date of first evidence of metastatic progression, or the date of death, whatever the cause</description>
  </other_outcome>
  <other_outcome>
    <measure>Toxicities of complementary treatment to induction tretatment</measure>
    <time_frame>3 months after the end of treatment</time_frame>
    <description>Rate of patients who received the whole of complementary treatment</description>
  </other_outcome>
  <other_outcome>
    <measure>QLQ-C30 questionnaires</measure>
    <time_frame>8 weeks, 6 months (3 months after the end of treatment) and 24 months after the end of treatment</time_frame>
    <description>These questionnaires assess the impact of the desease and treatment on tthe patient's life</description>
  </other_outcome>
  <other_outcome>
    <measure>QLQ-H&amp;N35 questionnaires</measure>
    <time_frame>8 weeks, 6 months (3 months after the end of treatment) and 24 months after the end of treatment</time_frame>
    <description>These questionnaires assess the impact of the desease and treatment on tthe patient's life</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">99</enrollment>
  <condition>Cancer of Head and Neck</condition>
  <arm_group>
    <arm_group_label>TPF (docetaxel, cisplatine, 5-FU)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Docetaxel, cisplatine, 5-FU administered, every 3 weeks for a total of 3 cycles</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TPFm (docetaxel, cisplatine, 5-FU) modifié</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Docetaxel, cisplatine, 5-FU administered, every 2 weeks for a total of 6 cycles</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <description>Docetaxel 75 mg/m² administered at D1 of each cure, every 3 weeks by intravenous infusion in 1 hour</description>
    <arm_group_label>TPF (docetaxel, cisplatine, 5-FU)</arm_group_label>
    <arm_group_label>TPFm (docetaxel, cisplatine, 5-FU) modifié</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>cisplatine 75 mg/m² administered at D1 of each cure, every 3 weeks by intravenous infusion in 1 hour</description>
    <arm_group_label>TPF (docetaxel, cisplatine, 5-FU)</arm_group_label>
    <arm_group_label>TPFm (docetaxel, cisplatine, 5-FU) modifié</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluoro Uracil</intervention_name>
    <description>750 mg/m²/j administered continuously at D1 to D5 of each cure, every 3 weeks by intravenous infusion ( so 120 hours)</description>
    <arm_group_label>TPF (docetaxel, cisplatine, 5-FU)</arm_group_label>
    <arm_group_label>TPFm (docetaxel, cisplatine, 5-FU) modifié</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Histologically proven squamous cell carcinoma of the head and neck from one or more of&#xD;
             the following primary sites: oral cavity, oropharynx, hypopharynx or larynx,&#xD;
             lymphadenopathy without front door&#xD;
&#xD;
          2. Inoperable tumor or tumor whose surgery would be multilating.&#xD;
&#xD;
             The non-operability criteria are:&#xD;
&#xD;
               -  Technically impossible resection: fixation / invasion of the tumor at the base of&#xD;
                  the skull or at the cervical vertebrae, nasopharynx involved, lymph nodes&#xD;
&#xD;
               -  Medical selection based on low surgical curability. This category includes all&#xD;
                  T3-T4 and all N2-N3 (AJCC 8th edition, June 2018)&#xD;
&#xD;
               -  Medical selection based on an organ preservation strategy&#xD;
&#xD;
          3. Patient not previously treated for ORL cancer&#xD;
&#xD;
          4. Age &gt; 18 and &lt; 75 years&#xD;
&#xD;
          5. PS 0 or 1 according to WHO&#xD;
&#xD;
          6. At least one lesion measurable according to the RECIST 1.1 criteria&#xD;
&#xD;
          7. Patient who can receive TPF according to the following criteria:&#xD;
&#xD;
               -  Adequate hematological function: neutrophils ³ 1.5 x 109 / l, platelets ³ 100 x&#xD;
                  109 / l, hemoglobin ³ 10 g / dl (or 6.2 mmol / l)&#xD;
&#xD;
               -  Adequate renal function: calculated creatinine clearance (Cockroft &amp; Gault) or&#xD;
                  measured ³ 60 ml / min.&#xD;
&#xD;
               -  Adequate liver function: normal total bilirubin; ASAT and ALAT less than or equal&#xD;
                  to 1.5 ´ LNS; PAL less than or equal to 2.5 X LNS&#xD;
&#xD;
               -  Grade &lt;2 peripheral neuropathy according to NCI CTCAE v5.0&#xD;
&#xD;
               -  No clinical impairment of hearing function&#xD;
&#xD;
               -  For patients aged 71 to 74, PS at 0 and considered non-geriatrically fragile (G8&#xD;
                  questionnaire and multidimensional assessments proposed by the GERICO group (ADL,&#xD;
                  MMSE, GDS scale, nutrition, motor skills and balance, geographic and personal&#xD;
                  situation and assessments) thymic))&#xD;
&#xD;
          8. Estimated life expectancy greater than or equal to 3 months&#xD;
&#xD;
          9. Weight loss of less than 10% during the 3 months before randomization&#xD;
&#xD;
         10. Patient understanding French and able to complete quality of life questionnaires&#xD;
&#xD;
         11. Patient having given written consent before any specific protocol procedure&#xD;
&#xD;
         12. Affiliation to a social security scheme or beneficiary of such a scheme&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Trans-glottic T3 with massive infiltration of the hemilarynx or T4 with massive&#xD;
             cartilage lysis or tumor of the retro-cricoarythenoid region or of the posterior&#xD;
             hypopharyngeal wall&#xD;
&#xD;
          2. Vaccination against recent or planned yellow fever&#xD;
&#xD;
          3. Known deficiency in dihydropyrimidine dehydrogenase (DPD) or determined by the&#xD;
             determination of uricemia.&#xD;
&#xD;
          4. History of other cancer except in situ cervical cancer or controlled basal cell&#xD;
             carcinoma. Patients in remission from cancer treated more than 3 years ago are&#xD;
             eligible. Patients treated by surgery alone for ORL cancer in the previous 3 years are&#xD;
             eligible.&#xD;
&#xD;
          5. Previous treatment of an ORL cancer by chemotherapy or radiotherapy Patients treated&#xD;
             by surgery alone for ORL cancer in the previous 3 years are eligible).&#xD;
&#xD;
          6. Presence of distant metastasis.&#xD;
&#xD;
          7. Participation in a therapeutic trial in the 30 days preceding randomization&#xD;
&#xD;
          8. Concomitant anticancer treatment&#xD;
&#xD;
          9. Patient under chronic treatment (3 months) with corticosteroid whose daily dosage is&#xD;
             20 mg / day of methylprednisolone or equivalent&#xD;
&#xD;
         10. Other existing serious medical pathologies (non-exhaustive list):&#xD;
&#xD;
               -  Uncontrolled cardiac pathology despite adequate treatment&#xD;
&#xD;
               -  Myocardial infarction in the 6 months preceding randomization&#xD;
&#xD;
               -  Neurological or psychiatric history such as dementia, convulsions&#xD;
&#xD;
               -  Active infection&#xD;
&#xD;
               -  Significant gastrointestinal abnormalities, including those that require&#xD;
                  parenteral nutrition, active peptic ulcer, and history of surgeries affecting&#xD;
                  absorption&#xD;
&#xD;
               -  Obstructive pulmonary disease requiring hospitalization in the year preceding&#xD;
                  randomization&#xD;
&#xD;
               -  Uncontrolled type II diabetes or other corticosteroid contraindications.&#xD;
&#xD;
               -  Moderate or severe eczema&#xD;
&#xD;
         11. Known hypersensitivity to docetaxel, cisplatin 5FU or one of their excipients.&#xD;
&#xD;
         12. Intended concomitant use of phenytoin, carbamazepine, barbiturates or rifampicin&#xD;
&#xD;
         13. Presence, upon selection, of psychological, family, social or geographic factors&#xD;
             likely to influence the patient's compliance with the study and monitoring protocol.&#xD;
&#xD;
         14. Pregnant or lactating woman&#xD;
&#xD;
         15. Patient (male or female) of reproductive age who is unable or unwilling to take&#xD;
             adequate contraceptive measures during treatment and up to 6 months after the last&#xD;
             treatment is administered.&#xD;
&#xD;
         16. Persons deprived of their liberty, under guardianship or curatorship&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>74 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Martial BINDZI</last_name>
    <phone>02 42 06 01 87</phone>
    <phone_ext>+33</phone_ext>
    <email>martial.bindzi@gortec.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Centre Leon Berard</name>
      <address>
        <city>Lyon</city>
        <zip>69008</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jérôme FAYETTE, MD</last_name>
      <phone>04 78 78 59 51</phone>
      <phone_ext>+33</phone_ext>
      <email>jerome.fayette@lyon.unicancer.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>April 10, 2020</study_first_submitted>
  <study_first_submitted_qc>April 20, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 22, 2020</study_first_posted>
  <last_update_submitted>February 12, 2021</last_update_submitted>
  <last_update_submitted_qc>February 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ORL cancer without front door, TPFm, inoperable tumor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Head and Neck Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

